FDA: The Mission and the Message

Abstract

This is the third article in a six-part series on new radiopharmaceuticals. Upon completion of this article, the nuclear medicine technologist will be able to (1) discuss the history of the FDA, (2) describe the process for new drug approval, (3) list possible causes for delay in new drug approval and the initiatives currently in place to streamline the review process, and (4) understand how the nuclear medicine community can improve its review submissions.